Back to Search
Start Over
Critical Differences between Induced and Spontaneous Mouse Models of Graves' Disease with Implications for Antigen-Specific Immunotherapy in Humans.
- Source :
-
Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2016 Dec 15; Vol. 197 (12), pp. 4560-4568. Date of Electronic Publication: 2016 Nov 09. - Publication Year :
- 2016
-
Abstract
- Graves' hyperthyroidism, a common autoimmune disease caused by pathogenic autoantibodies to the thyrotropin (TSH) receptor (TSHR), can be treated but not cured. This single autoantigenic target makes Graves' disease a prime candidate for Ag-specific immunotherapy. Previously, in an induced mouse model, injecting TSHR A-subunit protein attenuated hyperthyroidism by diverting pathogenic TSHR Abs to a nonfunctional variety. In this study, we explored the possibility of a similar diversion in a mouse model that spontaneously develops pathogenic TSHR autoantibodies, NOD.H2 <superscript>h4</superscript> mice with the human (h) TSHR (hTSHR) A-subunit transgene expressed in the thyroid and (shown in this article) the thymus. We hypothesized that such diversion would occur after injection of "inactive" hTSHR A-subunit protein recognized only by nonpathogenic (not pathogenic) TSHR Abs. Surprisingly, rather than attenuating the pre-existing pathogenic TSHR level, in TSHR/NOD.H2 <superscript>h4</superscript> mice inactive hTSHR Ag injected without adjuvant enhanced the levels of pathogenic TSH-binding inhibition and thyroid-stimulating Abs, as well as nonpathogenic Abs detected by ELISA. This effect was TSHR specific because spontaneously occurring autoantibodies to thyroglobulin and thyroid peroxidase were unaffected. As controls, nontransgenic NOD.H2 <superscript>h4</superscript> mice similarly injected with inactive hTSHR A-subunit protein unexpectedly developed TSHR Abs, but only of the nonpathogenic variety detected by ELISA. Our observations highlight critical differences between induced and spontaneous mouse models of Graves' disease with implications for potential immunotherapy in humans. In hTSHR/NOD.H2 <superscript>h4</superscript> mice with ongoing disease, injecting inactive hTSHR A-subunit protein fails to divert the autoantibody response to a nonpathogenic form. Indeed, such therapy is likely to enhance pathogenic Ab production and exacerbate Graves' disease in humans.<br /> (Copyright © 2016 by The American Association of Immunologists, Inc.)
- Subjects :
- Animals
Autoantibodies blood
Autoantigens immunology
Enzyme-Linked Immunosorbent Assay
Glycoprotein Hormones, alpha Subunit immunology
Glycoprotein Hormones, alpha Subunit metabolism
Graves Disease chemically induced
Graves Disease genetics
Graves Disease therapy
Humans
Immunotherapy trends
Mice
Mice, Inbred NOD
Mice, Transgenic
Receptors, Thyrotropin genetics
Receptors, Thyrotropin immunology
Disease Models, Animal
Graves Disease immunology
Immunotherapy methods
Receptors, Thyrotropin metabolism
Thymus Gland metabolism
Thyroid Gland metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1550-6606
- Volume :
- 197
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Journal of immunology (Baltimore, Md. : 1950)
- Publication Type :
- Academic Journal
- Accession number :
- 27913646
- Full Text :
- https://doi.org/10.4049/jimmunol.1601393